Vinpotropil in chronic cerebrovascular cognitive impairment
Observational study · 2010
- What was studied
- 349 patients with stage I–II dyscirculatory encephalopathy and cognitive impairment without dementia.
- Main finding
- The multicenter report describes improvement on repeat executive-function testing and in several self-reported symptoms after three months.
Reported findings and study design
Findings described in words
Multicenter before-and-after report in 349 patients given oral vinpocetine plus piracetam for three months.
Population or model 349 patients with stage I–II dyscirculatory encephalopathy and cognitive impairment without dementia.
Dose, route and schedule
One capsule containing 5 mg vinpocetine and 400 mg piracetam, three times daily for three months.
Protocol source ↗ · Indexed English abstract of the original Russian journal report.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Executive function and neurological symptoms | Improvement on repeat testing and symptom ratings was reported. | Three months |
The abstract does not report comparative effect sizes or adverse-event counts.
Source for these results ↗ · Reviewed 2026-11-14
Study limitations and source details
Study limitations
- The indexed abstract describes a treated cohort. It gives no independent comparator, effect sizes, arm counts or numerical adverse-event rates.
Source details
Indexed English abstract of the original Russian journal report.
Sources checked
Citation
V. V. Zakharov. Vinpotropil in chronic cerebrovascular cognitive impairment Zh Nevrol Psikhiatr Im S S Korsakova. 2010;110(11 Pt 1):13–16.